Breaking News Instant updates and real-time market news.

AAPL

Apple

$220.16

4.18 (1.94%)

, CPA

Copa Holdings

$76.94

0.12 (0.16%)

10:35
10/19/18
10/19
10:35
10/19/18
10:35

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Apple (AAPL) initiated with an Outperform at Wedbush. 2. Copa Holdings (CPA) initiated with an In-Line at Imperial Capital. 3. AMD initiated with a Sell at New Street Research. 4. Pacific Biosciences (PACB) initiated with an Outperform at Cowen. 5. ViewRay (VRAY) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

AAPL

Apple

$220.16

4.18 (1.94%)

CPA

Copa Holdings

$76.94

0.12 (0.16%)

AMD

AMD

$26.57

-0.04 (-0.15%)

PACB

Pacific Biosciences

$4.70

0.2 (4.44%)

VRAY

ViewRay

$9.85

0.43 (4.56%)

  • 24

    Oct

  • 01

    Nov

  • 06

    Nov

  • 08

    Nov

  • 06

    Dec

AAPL Apple
$220.16

4.18 (1.94%)

10/15/18
GSCO
10/15/18
NO CHANGE
Target $240
GSCO
Neutral
China consumer slowdown raises risk for Apple, says Goldman Sachs
Noting multiple signs of rapidly slowing consumer demand in China, Goldman Sachs analyst Rod Hall said he sees risk to demand for Apple's products, adding that much of his view of Apple's upside potential was centered on Chinese demand for larger screen sizes. However, he also flags the offsetting positive trend of 6"+ phone conversions in both China and elsewhere. While Hall reiterates his December quarter iPhone shipments estimate of 80M and keeps a Neutral rating and $240 price target on Apple shares, he sees risk that Apple's potential to "beat and raise" in Q4 is likely reduced should weak consumer demand persist in China.
10/18/18
MSCO
10/18/18
NO CHANGE
Target $247
MSCO
Overweight
Morgan Stanley says China a near-term headwind for Apple's App Store growth
Morgan Stanley analyst Katy Huberty noted that data from Sensor Tower imply App Store net revenue recognized by Apple of $3.6B in the September quarter, which would be a quarterly high but below her forecast of $3.8B. Assuming her other estimates for Services are correct, this would imply September quarter Services revenue of $9.8B, which Huberty notes would be below her current $10.0B estimate and below the current consensus of $10.1B. She said a pause in new gaming approvals in China, coupled with fear of economic slowdown there, present a near-term headwind for App Store growth, but she sees limited downside to near-term Apple estimates and remains bullish on Services growth over the longer-term. Huberty keeps an Overweight rating and $247 price target on Apple shares.
10/18/18
WEDB
10/18/18
INITIATION
WEDB
Outperform
Apple initiated with an Outperform at Wedbush
10/19/18
WEDB
10/19/18
INITIATION
Target $310
WEDB
Outperform
Wedbush starts Apple with Outperform rating and $310 price target
Wedbush analyst Daniel Ives last night initiated coverage of Apple with an Outperform rating and $310 price target. The analyst added the shares to his firm's Best Ideas List. He believes pent-up demand will upside to 2019 iPhone shipment estimates. An analysis shows that 350M iPhones are in the "window of opportunity" to upgrade over the next 12 to 18 months, Ives tells investors in a research note. Further, the analyst believes the features and pricing for the new iPhones help put Chinese consumers "front and center."
CPA Copa Holdings
$76.94

0.12 (0.16%)

09/12/18
BUCK
09/12/18
UPGRADE
BUCK
Buy
Copa Holdings upgraded to Buy from Neutral at Buckingham
09/28/18
UBSW
09/28/18
DOWNGRADE
UBSW
Neutral
Copa Holdings downgraded to Neutral from Buy at UBS
10/19/18
IMPC
10/19/18
INITIATION
Target $86
IMPC
In-Line
Copa Holdings initiated with an In-Line at Imperial Capital
Imperial Capital analyst Michael Derchin started Copa Holdings with an In-Line rating and $86 price target. The analyst expects the company's earnings growth to be limited through fiscal 2019 due to macroeconomic headwinds and higher fuel prices.
09/12/18
09/12/18
UPGRADE
Target $95

Buy
Copa Holdings upgraded to Buy on valuation at Buckingham
As previously reported, Buckingham upgraded Copa Holdings to Buy from Neutral and cut its price target to $95 from $103. Analyst Daniel McKenzie thinks his upgrade might be a "little early" and trimmed Copa estimates to reflect FX volatility in key end markets and slightly higher competitive capacity, but said shares are 23% off a recent high, and largely discount earnings risk. McKenzie said booking trends have reflected positively over each of the past 3 weeks, indicating demand and pricing are stabilizing at lower levels, and the new revenue management system is poised to contribute to new ancillary revenue opportunities.
AMD AMD
$26.57

-0.04 (-0.15%)

10/01/18
10/01/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. OPCO CUTS CHIPOTLE TO UNDERPERFORM: Oppenheimer analyst Brian Bittner downgraded Chipotle Mexican Grill (CMG) to Underperform from Perform with a $400 price target. Since its new CEO announcement in February, Chipotle is up 82% and has been upgraded 10 different times by the Street, Bittner noted. The company's "high-flying" valuation has "priced in" persistent mid-single same-store-sales and a path to at least $20 of earnings per share versus $8-$9 this year, the analyst added. His work suggests this earnings path is too optimistic, even when assuming "healthy sales." INTEL CUT TO UNDERWEIGHT BY BARCLAYS: Barclays analyst Blayne Curtis downgraded Intel (INTC) to Underweight from Equal Weight and lowered his price target for the shares to $38 from $53. End-market tailwinds that propelled the run in shares, namely PC shortages and the slowing of server growth, are likely to reverse, Curtis believes. Further, the analyst expects Intel will see increased competition from AMD (AMD) and declining free cash flow returns. In addition, the names that have been floated in the CEO search "have yet to yield any disruptive potential candidates to take on all of these challenges," Curtis said. By squandering its manufacturing lead, the company now faces a "costly battle to retain share amidst a near-term slowing of its end markets," concluded the analyst. MKM CUTS INFINERA TO SELL: MKM Partners analyst Michael Genovese downgraded Infinera (INFN) to Sell from Neutral and lowered his price target to $5.50 from $10. The analyst said his checks suggest the company's loss of its biggest customer CenturyLink (CTL) to Ciena (CIEN) amid concerns with its ability to produce "new leading edge digital signal processors every 18-30 months". Genovese expects Infinera's upcoming guidance for Q4 and FY19 to be disappointing on revenues and margins, while his price target that assumes a valuation multiple of 0.8-times enterprise value to expected FY19 sales "reflects increasing concerns about the long-term competitiveness of the company." TEVA UPGRADED AT LEERINK, GOLDMAN: Leerink analyst Ami Fadia upgraded Teva (TEVA) to Market Perform from Underperform due to improving business fundamentals as well as the improving multiples for the overall generics sector. The analyst, who believes the company's fundamentals have improved meaningfully and put Teva in a position to pay down $3.5B in debt by YE18, raised his price target on the shares to $24 from $16. Meanwhile, Goldman Sachs analyst Jami Rubin added Teva to Goldman's Conviction List with a Buy rating, calling the recent selloff in the shares a "head scratcher." Recent concerns raised in the marketplace regarding second half of 2018 headwinds and Eli Lilly's (LLY) galcenuzemab approval were already expected and well understood, Rubin tells investors in a research note. DEUTSCHE CUTS LAM RESEARCH, APPLIED MATERIALS TO HOLD: Deutsche Bank analyst Sidney Ho downgraded Lam Research (LRCX) to Hold and lowered his price target for the shares to $170 from $230, and downgraded Applied Materials (AMAT) to Hold and lowered his price target for the shares to $43 from $58. Semicap Equipment stocks are not expensive but lack positive catalysts, Ho said. The analyst believes investor fears over that the industry has reached a cyclical peak will remain as long as the memory market stays weak. Further, he sees risk is for additional capex push-outs, especially in the first half of 2019.
10/05/18
BOFA
10/05/18
NO CHANGE
BOFA
Buy
AMD lead over Intel within 7nm server remains intact, says BofA/Merrill
BofA Merrill Lynch analyst Vivek Arya noted that AMD (AMD) shares have underperformed Intel's (INTC) by about 28 percentage points since September 12 amid media reports that the latter is accelerating purchases of 10nm equipment. Intel's recent backing of its 2018 outlook also threw cold water on some bullish expectations for AMD to capture share in current-generation technology, add Arya. However, while Intel can slightly improve launch timing for next-gen 10nm-based PC processors, the launch of the more critical server parts is still unlikely before mid-2020, at-best, Arya believes. Also, AMD's 6 to 9 month lead with its 7nm server chips, which are already sampling, remains intact, said the analyst, who keeps a Buy rating on AMD and Neutral rating on Intel shares.
10/18/18
COWN
10/18/18
NO CHANGE
Target $33
COWN
Outperform
AMD price target raised to $33 from $30 at Cowen
Cowen analyst Matthew Ramsay raised his price target on AMD (AMD) to $33 from $30 as he believes fundamentals remain in place to keep the company on a path of sustainable market share gains across the CPU franchise. The analyst also feels AMD is well positioned to pounce on the consequences of Intel's (INTC) recent missteps. Ramsay reiterated his Outperform rating on AMD shares.
10/19/18
NWST
10/19/18
INITIATION
Target $18
NWST
Sell
New Street Research starts AMD with Sell rating, $18 price target
New Street Research analyst Pierre Ferragu initiated coverage of AMD (AMD) with a Sell rating and $18 price target. The chipmaker closed yesterday at $26.62. AMD "cannot win sustainably and beyond a niche positioning," Ferragu tells investors in a research note. While the company performed very well in recent years, its competitive positioning against Intel (INTC) is "tough," Ferragu contends. He expects "signs of slowdown" or indications of a competitive response by Intel to materialize by the end of 2019. As such, the analyst sees a "hard stop around the corner" for AMD.
PACB Pacific Biosciences
$4.70

0.2 (4.44%)

10/05/18
PIPR
10/05/18
NO CHANGE
Target $3.8
PIPR
Neutral
Pacific Biosciences checks show Sequels placements decline, says Piper Jaffray
Piper Jaffray analyst William Quirk says channel checks found 10 Sequels placed in Q3, which suggests Pacific Biosciences had a sequential decline in placements, consistent with management comments. The analyst found 15 placements in his Q2 checks. Quirk trimmed his Q3 instrument expectations from 27 Sequels to 20 and his instrument revenue forecast by $2.2M to $6.4M. Despite being encouraged with the company's continued progress on the 8M chip, he remains Neutral on the shares ahead of the earnings release.
08/09/18
08/09/18
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Pacific Biosciences (PACB) initiated with an Overweight at Cantor Fitzgerald by analyst Jordan Abrams, who thinks Pacific's long-read next generation sequencing platform is the industry standard for deep genomic analysis in human, plant, and animal genomes, as well as RNA. 2. Heico (HEI) initiated with a Neutral at Baird. 3. Zynga (ZNGA) initiated with an Underweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/09/18
CANT
08/09/18
INITIATION
Target $5
CANT
Overweight
Cantor starts Pacific Biosciences with Overweight rating, $5 target
Cantor Fitzgerald analyst Jordan Abrams last night initiated coverage of Pacific Biosciences of California with an Overweight rating and $5 price target. The analyst thinks Pacific's long-read next generation sequencing platform is the industry standard for deep genomic analysis in human, plant, and animal genomes, as well as RNA. While the company has seen mixed revenue performance over the past three years, it is "getting close to an inflection point," which the Street is missing, Abrams told investors in a research note. He sees "multiple paths to revenue acceleration."
10/19/18
COWN
10/19/18
INITIATION
Target $7
COWN
Outperform
Pacific Biosciences initiated with an Outperform at Cowen
Cowen analyst Doug Schenkel initiated Pacific Biosciences with an Outperform rating, stating that the company will be well positioned for a growth inflection following the launch of its 8M chip in 2019. He said the chip will compete at price and be comparable to others without compromising on its differentiated attributes. Schenkel has a $6.50 price target on Pacific Biosciences shares.
VRAY ViewRay
$9.85

0.43 (4.56%)

07/03/18
JEFF
07/03/18
INITIATION
Target $12
JEFF
Buy
ViewRay initiated with a Buy at Jefferies
Jefferies analyst Anthony Petrone started ViewRay with a Buy rating and $12 price target. The analyst believes the company is best positioned to capture early MR-linac adoption given its first mover advantage and growing body of clinical evidence. He believes ViewRay's MRIdian has competitive advantages over Elekta's MR-linac system.
07/03/18
07/03/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Veru Inc. (VERU) initiated with a Buy at Maxim. 2. ViewRay (VRAY) initiated with a Buy at Jefferies. 3. MeiraGTx (MGTX) initiated with an Overweight at Barclays. 4. Zafgen (ZFGN) initiated with an Overweight at Piper Jaffray. 5. Eloxx Pharmaceuticals (ELOX) initiated with a Buy at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/25/18
NORL
07/25/18
NO CHANGE
Target $20
NORL
Outperform
Northland 'extremely bullish' on ViewRay changes, ups target to $20
Northland analyst Suraj Kali is "extremely bullish" on the management and board changes announced by ViewRay. The changes signal a new focus on operational execution and potentially a "packaging" of ViewRay for a potential sale in the next few years, Kali tells investors in a research note. The analyst points out that Scott Drake and Keith Grossman bring an M&A perspective to ViewRay having sold their respective companies over the last few years. Kali raised his price target for the shares to $20 from $13 and keeps an Outperform rating on the name. With "Wall Street savvy" operators now the company, the analyst is "more convinced than ever that ViewRay will be another strategic sale in due time."
10/19/18
BARD
10/19/18
INITIATION
Target $14
BARD
Outperform
ViewRay initiated with an Outperform at Baird
Baird analyst Jason Bednar initiated ViewRay with an Outperform rating as he sees a multi-year path for MR-linac to transition from simply being a "cool academic tool" to being a widely preferred treatment approach for multiple tumor sites. Bednar has a $14 price target on ViewRay shares.

TODAY'S FREE FLY STORIES

02:35
11/21/18
11/21
02:35
11/21/18
02:35
General news
FX Update: The Dollar majors have traded mixed »

FX Update: The Dollar…

02:00
11/21/18
11/21
02:00
11/21/18
02:00
General news
FX Action: USD-JPY has traded moderately firmer »

FX Action: USD-JPY has…

01:45
11/21/18
11/21
01:45
11/21/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

MDT

Medtronic

$92.31

1.91 (2.11%)

20:48
11/20/18
11/20
20:48
11/20/18
20:48
Recommendations
Medtronic analyst commentary at Piper Jaffray »

Medtronic in the midst of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

RDY

Dr. Reddy's

$36.48

1.19 (3.37%)

20:44
11/20/18
11/20
20:44
11/20/18
20:44
Hot Stocks
Dr. Reddy's announces favorable outcome in Buprenorphine and Naloxone litigation »

Dr. Reddy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCCO

Southern Copper

$35.63

-1.615 (-4.34%)

20:30
11/20/18
11/20
20:30
11/20/18
20:30
Upgrade
Southern Copper rating change at Bradesco »

Southern Copper upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBH

KB Home

$19.84

0.37 (1.90%)

20:17
11/20/18
11/20
20:17
11/20/18
20:17
Hot Stocks
KB Home expands into Seattle housing market »

KB Home announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDR

Cloudera

$10.69

-0.545 (-4.85%)

20:16
11/20/18
11/20
20:16
11/20/18
20:16
Hot Stocks
Cloudera partners with Bank Rakyat Indonesia »

Cloudera announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

AAPL

Apple

$177.10

-8.7 (-4.68%)

19:44
11/20/18
11/20
19:44
11/20/18
19:44
Periodicals
Apple acquires AI software firm Silk Labs, The Information reports »

Apple is said to have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

NVT

nVent Electric

$24.18

-0.35 (-1.43%)

19:20
11/20/18
11/20
19:20
11/20/18
19:20
Initiation
nVent Electric initiated at Vertical Research »

nVent Electric initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

FB

Facebook

$132.47

0.85 (0.65%)

19:13
11/20/18
11/20
19:13
11/20/18
19:13
Periodicals
Russia's FAN sues Facebook, claims to be legitimate news outlet, Reuters says »

Facebook is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

CMCSA

Comcast

$36.75

-1.44 (-3.77%)

, CMCSK

Comcast

$0.00

(0.00%)

18:58
11/20/18
11/20
18:58
11/20/18
18:58
Periodicals
Megyn Kelly seen to leave NBC News with entirety of $69M deal, WSJ says »

Megyn Kelly is…

CMCSA

Comcast

$36.75

-1.44 (-3.77%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

FL

Foot Locker

$46.10

-2.69 (-5.51%)

, ADSK

Autodesk

$122.99

-2.76 (-2.19%)

18:56
11/20/18
11/20
18:56
11/20/18
18:56
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Foot…

FL

Foot Locker

$46.10

-2.69 (-5.51%)

ADSK

Autodesk

$122.99

-2.76 (-2.19%)

BJ

BJ's Wholesale

$19.85

-0.22 (-1.10%)

KEYS

Keysight Technologies

$54.35

-1.23 (-2.21%)

CPRT

Copart

$47.30

-1.255 (-2.58%)

VNET

21Vianet

$11.20

-0.1 (-0.88%)

GPS

Gap

$24.65

-0.79 (-3.11%)

BILI

Bilibili

$13.61

0.575 (4.41%)

DXCM

DexCom

$119.89

-1.34 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 26

    Nov

  • 27

    Nov

  • 04

    Dec

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 03

    Mar

AAPL

Apple

$177.10

-8.7 (-4.68%)

18:46
11/20/18
11/20
18:46
11/20/18
18:46
Periodicals
Apple in discussions to give vets access to electronic medical records, WSJ says »

Apple is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

FB

Facebook

$132.47

0.85 (0.65%)

18:32
11/20/18
11/20
18:32
11/20/18
18:32
Periodicals
Facebook ads system was down today for some users, Bloomberg says »

Facebook's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

EMCI

EMC Insurance

$32.33

1.1 (3.52%)

18:28
11/20/18
11/20
18:28
11/20/18
18:28
Hot Stocks
EMC Insurance announces receipt of proposal from EMCC to buy all of its shares »

EMC Insurance announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEX

Emerald Expositions Events

$11.09

0.17 (1.56%)

18:26
11/20/18
11/20
18:26
11/20/18
18:26
Hot Stocks
Emerald Expositions Events announces $20M share repurchase program »

The company anticipates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIVN

LivaNova

$98.00

-22.28 (-18.52%)

18:26
11/20/18
11/20
18:26
11/20/18
18:26
Recommendations
LivaNova analyst commentary at Piper Jaffray »

LivaNova price decline on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 27

    Nov

BKH

Black Hills

$64.40

0.92 (1.45%)

18:24
11/20/18
11/20
18:24
11/20/18
18:24
Hot Stocks
Black Hills Energy receives approval to construct $54M gas pipeline in Wyoming »

Black Hills announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,026.00

7 (0.69%)

, GOOGL

Alphabet Class A

$1,031.22

4.99 (0.49%)

18:19
11/20/18
11/20
18:19
11/20/18
18:19
Periodicals
Google expands Moffett Park presence again, SVBJ says »

Google is once again…

GOOG

Alphabet

$1,026.00

7 (0.69%)

GOOGL

Alphabet Class A

$1,031.22

4.99 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Mar

SE

Sea Limited

$12.18

-0.52 (-4.09%)

18:04
11/20/18
11/20
18:04
11/20/18
18:04
Earnings
Sea Limited reports Q3 net loss ($237.6M) vs. ($127.1M) last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BILI

Bilibili

$13.61

0.575 (4.41%)

18:03
11/20/18
11/20
18:03
11/20/18
18:03
Earnings
Bilibili reports Q3 revenue $157.1M, consensus $146.72M »

Reports Q3 adjusted net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

LTM

Latam Airlines

$9.24

-0.4 (-4.15%)

18:01
11/20/18
11/20
18:01
11/20/18
18:01
Hot Stocks
Breaking Hot Stocks news story on Latam Airlines »

LATAM Airlines reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CE

Celanese

$100.26

-1.53 (-1.50%)

18:01
11/20/18
11/20
18:01
11/20/18
18:01
Hot Stocks
Celanese increases Fortron polyphenylene sulphide price by 85c per kg »

The price increases will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$317.77

-3.09 (-0.96%)

, TSLA

Tesla

$347.60

-5.88 (-1.66%)

17:55
11/20/18
11/20
17:55
11/20/18
17:55
Periodicals
NASA to investigate workplace culture at Boeing, SpaceX, Reuters says »

NASA said that it plans…

BA

Boeing

$317.77

-3.09 (-0.96%)

TSLA

Tesla

$347.60

-5.88 (-1.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 13

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.